SYDNEY (Reuters) – Australian biotech company Ena Respiratory said on Monday that a nasal spray it is developing to improve the human immune system and fight colds and flu significantly reduced coronavirus growth in a recent animal study.
A ferret study showed that the product called INNA-051, which could be used as a complement to vaccines, lowered levels of the virus that causes COVID-19 by up to 96 percent, the company said. The study was conducted by the British government agency Public Health England.
Ena Respiratory said it would be ready to test INNA-051 in human studies in less than four months, subject to successful toxicity studies and regulatory approval.
The company raised AUS $ 1
Several companies around the world are trying to develop a coronavirus vaccine. Australia has entered into deals with some pharmaceutical companies that invest billions to secure potential vaccines for COVID-19, which has killed over 992,000 people worldwide.
Australia has reported 875 deaths and just over 27,000 coronavirus cases so far, far fewer than the numbers reported in other developed countries.
(Reporting by Renju Jose; Editing by Ana Nicolaci da Costa)